Supplemental material
Drug Delivery
Volume 25, 2018 - Issue 1
Related Research Data
Pulmonary Drug Delivery: Novel Pharmaceutical Technologies Breathe New Life into the Lungs
Source:
Parenteral Drug Association, Inc.
Cancer statistics, 2017
Source:
Wiley
Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung Cancer
Source:
American Society of Clinical Oncology (ASCO)
Inhalation delivery of topotecan is superior to intravenous exposure for suppressing lung cancer in a preclinical model
Source:
Taylor & Francis
Southwest Oncology Group S0802: A Randomized, Phase II Trial of Weekly Topotecan With and Without Ziv-Aflibercept in Patients With Platinum-Treated Small-Cell Lung Cancer
Source:
American Society of Clinical Oncology (ASCO)
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
Source:
Proceedings of the National Academy of Sciences
A Randomized Phase II Trial of Oral Topotecan Versus Docetaxel in the Second-Line Treatment of Non–Small-Cell Lung Cancer
Source:
Elsevier BV
Inhaling medicines: delivering drugs to the body through the lungs
Source:
Springer Science and Business Media LLC
A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancer
Source:
Elsevier BV
Association of Inhalation Toxicologists (AIT) Working Party Recommendation for Standard Delivered Dose Calculation and Expression in Non-Clinical Aerosol Inhalation Toxicology Studies with Pharmaceuticals
Source:
Informa UK Limited
Inhalation delivery of topotecan is superior to intravenous exposure for suppressing lung cancer in a preclinical model
Source:
figshare Academic Research System
Combination Therapy with Vidaza and Entinostat Suppresses Tumor Growth and Reprograms the Epigenome in an Orthotopic Lung Cancer Model
Source:
American Association for Cancer Research (AACR)
Recent Advances with Topotecan in the Treatment of Lung Cancer
Source:
Alphamed Press
Regional Lung Deposition and Bronchodilator Response as a Function of β2-Agonist Particle Size
Source:
American Thoracic Society
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Source:
New England Journal of Medicine (NEJM/MMS)
Global Cancer Statistics, 2012
Source:
Wiley
Inhalation delivery of topotecan is superior to intravenous exposure for suppressing lung cancer in a preclinical model
Source:
Taylor & Francis
Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer
Source:
American Society of Clinical Oncology (ASCO)
Emerging inhalation aerosol devices and strategies: Where are we headed?
Source:
Elsevier BV
Aerosolized Chemotherapy
Source:
Mary Ann Liebert Inc
Phase II study of topotecan in metastatic non-small-cell lung cancer.
Source:
American Society of Clinical Oncology (ASCO)
New driver mutations in non-small-cell lung cancer
Source:
Elsevier BV
Phase I and Pharmacologic Study of Weekly Bolus Topotecan for Advanced Non–Small-Cell Lung Cancer
Source:
Elsevier BV
Phase II Trial of Topotecan Administered as a 21-Day Continuous Infusion in Previously Untreated Patients With Stage IIIB and IV Non-Small-Cell Lung Cancer
Source:
Ovid Technologies (Wolters Kluwer Health)
Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer
Source:
American Society of Clinical Oncology (ASCO)
ALI multilayered co-cultures mimic biochemical mechanisms of the cancer cell-fibroblast cross-talk involved in NSCLC MultiDrug Resistance
Source:
Springer Science and Business Media LLC
Phase III Study Comparing Oral Topotecan to Intravenous Docetaxel in Patients With Pretreated Advanced Non–Small-Cell Lung Cancer
Source:
American Society of Clinical Oncology (ASCO)
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
Source:
Public Library of Science (PLoS)
An Alternative Inhibitor Overcomes Resistance Caused by a Mutation of the Epidermal Growth Factor Receptor
Source:
American Association for Cancer Research (AACR)
Inspiratory Flows and Volumes in Subjects with Non-CF Bronchiectasis Using a New Dry Powder Inhaler Device
Source:
Bentham Science Publishers Ltd.
Causes of Death of Patients With Lung Cancer
Source:
Archives of Pathology and Laboratory Medicine
Respiratory Tract Deposition of HFA–Beclomethasone and HFA–Fluticasone in Asthmatic Patients
Source:
Mary Ann Liebert Inc
Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model
Source:
Springer Nature
Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy.
Source:
American Society of Clinical Oncology (ASCO)
Linking provided by
